IMPORTANT: Pharmacy Assurance is going through a phased roll-out and currently is only available to Clinical Trials of Investigational Medicinal Products (CTIMPs). The information below is only relevant to applications going through the combined review service. It is no longer possible for CTIMP applications to be made using this part of IRAS.
|
Pharmacy Assurance simplifies the pharmacy capacity and capability assessments carried out by participating NHS/HSC sites by providing a single technical pharmacy review, which is accepted by all participating NHS/HSC sites. This replaces the need to complete separate technical reviews at each participating NHS/HSC organisation. The single review therefore speeds up the site set-up process, meaning research activities can start much quicker.
Pharmacy Assurance uses a standardised technical pharmacy review form and all pharmacy reviewers must have undergone Pharmacy Assurance training before they can conduct Pharmacy Assurance reviews. This ensures consistency in the process across different Trusts and Health Boards. The HRA holds a list of registered Pharmacy Assurance reviewers who can conduct the technical reviews for Pharmacy Assurance. You can download the latest list of registered reviewers from the HRA website.
Pharmacy Assurance has also introduced a standardised review fee per reviewer. This review fee may be applicable to your study. You can find more information about this standardised fee in the Payment Framework Guidance. Please note that some studies may need to be reviewed by more than one registered reviewer depending on the clinical specialisms involved in the trial, such as those involving radiopharmacy.
For further information about the benefits of Pharmacy Assurance please refer to the HRA website.
Pharmacy Assurance is UK-wide but the process varies depending on the location of the lead nation for the study. NHS/HSC sponsors in the UK are expected to submit their eligible studies through Pharmacy Assurance. All other non-NHS/HSC sponsors are strongly encouraged to submit for Pharmacy Assurance. For details on how to apply for Pharmacy Assurance please select one of the following options:
This page also provides guidance on:
Eligibility
Where the lead nation is England or Wales, Pharmacy Assurance is available for Phase I - III clinical trials involving investigational medicinal products (CTIMPs) which are taking place in multiple secondary care sites in the NHS/HSC.
Review Routes
Where the lead nation is England or Wales, there are two Pharmacy Assurance review routes to choose from;
HRA-managed or
Self-managed. The table below outlines the differences between these two review routes.
|
HRA-managed
|
Self-managed
|
Overview
|
The entire process is managed by the HRA on behalf of the applicant. The HRA will work directly with both the applicant and with the reviewer. Any queries raised by the reviewer will be cascaded to the applicant by the HRA. |
The applicant will manage the review process themselves. The applicant will work directly with both the reviewer and the HRA. |
Sponsor eligibility
|
N/A |
The study must be sponsored by the NHS, either as the main sponsor or as a co-sponsor. |
Reviewer requirements
|
The HRA will select an appropriate reviewer from the list of registered reviewers.
or
The applicant can choose up to three trusts/health boards and the HRA will select a reviewer from these where possible. There may be instances where this request cannot be accommodated. In such instances, an alternative reviewer will be selected.
|
The applicant selects the reviewer themselves. The reviewer must be:
- on the HRA list of registered reviewers
- employed by the study sponsor (or co-sponsor) Trust or Health Board
- involved in the development of the study documents and set up of the study (in particular the sourcing, packaging, and labelling of any investigational medicinal products (IMPs)).
|
Fee requirements
|
The standard review fee is applicable per reviewer.
Further information is available in the Payments Framework Guidance. |
Any review fee charged is at the discretion of the organisation employing the reviewer(s).
Further information is available in the Payments Framework Guidance.
|
When to apply
|
Pharmacy Assurance is a pre-submission review.
You can apply for Pharmacy Assurance at any time point up to and including the date on which you e-submit your IRAS Form for HRA and HCRW Approval. Where possible we recommend that studies are submitted as early as possible before e-submission for HRA and HCRW Approval
|
Confirmation of Pharmacy Assurance
|
The outcome of Pharmacy Assurance will be confirmed by the HRA via email, regardless of which review route is taken. The email confirmation provided by the HRA should be used as proof of Pharmacy Assurance. |
Back to the top
For HRA-managed studies, the HRA works with the selected reviewer(s) to complete Pharmacy Assurance for your study. The sequence of events for applications made via the HRA-managed route is detailed below.
- You (the applicant) should send the application pack and, if applicable, the HRA/Centrally-Managed Reviewer Request Form to pharmacy.assurance@hra.nhs.uk to begin the Pharmacy Assurance process.
- The HRA will check to ensure that all the appropriate documents have been submitted. You'll receive an email from the HRA confirming when you've met the submission requirements.
- The HRA will assign appropriate HRA-registered pharmacy reviewers to complete the technical review. Note:
- If an HRA/Centrally-Managed Reviewer Request Form was submitted, the HRA will assign requested reviewers wherever possible. Where the requested reviewers are not available the HRA will contact you. You can then choose to either:
- wait for the requested reviewers to become available and delay Pharmacy Assurance
- request the HRA choose the first available, appropriate reviewers
- If you've not requested specific reviewers the HRA will select the first available, appropriate reviewers.
- The HRA will share your contact details with the reviewers so that payment arrangements can be made.
- Where queries arise during the review, the HRA will work with you on behalf of the pharmacy reviewers to resolve the queries.
- The reviewers send the completed review form to the HRA.
- The HRA will send the completed review to you and confirm Pharmacy Assurance. The HRA aims to send this email within 30 calendar days of the initial application for Pharmacy Assurance (excluding any time taken to resolve queries during review).
- You send the completed review and confirmation of the Pharmacy Assurance email to participating NHS sites in England and Wales. If the review and confirmation email are available before you send out the Local Information Pack to participating NHS sites in England and Wales, you can include them as part of the Local Information Pack. If you have participating NHS sites in Scotland the NHS Research Scotland Permissions Coordinating Centre (NRSPCC) will share this with R&D teams at participating sites. If you have HSC sites in Northern Ireland the Research Gateway will share this with participating HSC sites on your behalf.
Back to the top
For self-managed studies you'll need to register the trial as self-managed with the HRA and then work with the selected reviewer(s) to complete Pharmacy Assurance for your trial. You should therefore identify the reviewer(s) who will complete the review before you make a submission. The sequence of events
for applications made via the self-managed route is detailed below.- You (the applicant) should send the Self-Managed Registration Form and relevant information in the covering email from the application pack to pharmacy.assurance@hra.nhs.uk to begin the Pharmacy Assurance process.
- Within 7 calendar days of you submitting all the required documents to the HRA, the HRA will:
- Ensure you plan to use HRA-registered reviewers with appropriate specialisms to review the study; and
- Email you to confirm that the study has been registered for a self-managed review. They'll also provide you with a copy of the technical pharmacy review form for the reviewer(s) to complete.
- You then request the review from the pharmacy reviewers by forwarding the email from the HRA and the full Pharmacy Assurance application pack.
- You and the pharmacy reviewers work with one another to complete the review. There are no timelines set by the HRA for this part of the process.
- The reviewers send the completed pharmacy review to you.
- You send the completed pharmacy review to the HRA (pharmacy.assurance@hra.nhs.uk).
- The HRA will issue confirmation of Pharmacy Assurance via email. You then send the completed review and confirmation of the Pharmacy Assurance email to participating NHS sites. You should note the following
- If the review and confirmation email are available before you send out the Local Information Pack to participating NHS sites in England and Wales, you can include them as part of the Local Information Pack.
- If you have participating NHS sites in Scotland the NHS Research Scotland Permissions Coordinating Centre (NRSPCC) will share this with R&D teams at participating sites.
- If you have HSC sites in Northern Ireland the Research Gateway will share this with participating HSC sites on your behalf.
Back to the top
Eligibility
Where the lead nation is Northern Ireland, Pharmacy Assurance is available for Phase I-III clinical trials involving investigational medicinal product(s) (CTIMPs) which are taking place in multiple secondary care sites in the NHS/HSC.
Review Routes
Where the lead nation is Northern Ireland, there are two Pharmacy Assurance review routes to choose from;
Centrally-managed or
Self-managed. The table below outlines the differences between these two review routes.
|
Centrally-managed
|
Self-managed
|
Overview
|
The process is managed by the HSC R&D Application Gateway on behalf of the applicant. The Research Gateway will manage the application process, selection of reviewer and confirm completion of review. The reviewer and applicant will work directly with each other to address queries raised during the review.
|
The applicant will manage the review process themselves, including the selection of reviewers. The applicant will work directly with both the reviewer and the Research Gateway. |
Sponsor eligibility
|
N/A |
The study must be sponsored by the HSC Trust, either as the main sponsor or as a co-sponsor. |
Reviewer requirements
|
The Research Gateway will select an appropriate reviewer from the list of registered reviewers.
or
The applicant can choose up to three trusts and the Research Gateway will select a reviewer from these where possible. There may be instances where this request cannot be accommodated. In such instances, an alternative reviewer will be selected.
|
The applicant selects the reviewer themselves. The reviewer must be:
- on the HRA list of registered reviewers
- employed by the study sponsor (or co-sponsor) Trust
- involved in the development of the study documents and set up of the study (in particular the sourcing, packaging, and labelling of any investigational medicinal products (IMPs)).
|
Fee requirements
|
The standard review fee is applicable per reviewer.
Further information is available in the Payments Framework Guidance. |
Any review fee charged is at the discretion of the organisation employing the reviewer(s).
Further information is available in the Payments Framework Guidance.
|
When to apply
|
Pharmacy Assurance is a pre-submission review.
You can apply for Pharmacy Assurance at any time point up to and including the date on which you e-submit your IRAS Form for governance review, however, where possible we recommend that studies are submitted as early as possible before e-submission for governance review.
|
Confirmation of Pharmacy Assurance
|
The outcome of Pharmacy Assurance will be confirmed by the Research Gateway via email, regardless of which review route is taken. The email confirmation provided by the HSC should be used as proof of Pharmacy Assurance. |
Back to the top
For Centrally-managed studies, the Research Gateway works with the selected reviewer(s) to complete Pharmacy Assurance for your study. The sequence of events
for applications made via the centrally-managed route is detailed below.
- You (the applicant) should send the application pack and, if applicable, the HRA/Centrally-Managed Reviewer Request Form to pharmacytechnicalassurance@hscni.net to begin Pharmacy Assurance.
- The Research Gateway will check to ensure that all the appropriate documents have been submitted. You'll receive an email from the Research Gateway confirming when you've met the submission requirements.
- The Research Gateway will assign appropriate HRA-registered pharmacy reviewers to complete the technical review. Note:
- If an HRA/Centrally-Managed Reviewer Request Form was submitted, the Research Gateway will assign requested reviewer(s) wherever possible. Where the requested reviewer(s) is/are not available the Research Gateway will contact you. You can then choose to:
- wait for the requested reviewer(s) to become available and delay Pharmacy Assurance
- request the Research Gateway choose the first available, appropriate reviewer(s)
- If you've not requested specific reviewer(s) the Research Gateway will select the first available, appropriate reviewer(s).
- The Research Gateway will share your contact details with the reviewer(s) so that payment arrangements can be made.
- Where queries arise during the review, the pharmacy reviewer(s) will work with you directly to resolve the queries.
- The reviewer(s) send the completed review form to the Research Gateway.
- The Research Gateway will send the completed review to you and confirm Pharmacy Assurance. The Research Gateway aims to send this email within 30 calendar days of the initial application for Pharmacy Assurance (excluding any time taken to resolve queries during review).
- The Research Gateway will share the completed review and confirmation of Pharmacy Assurance with participating HSC sites in Northern Ireland. If you have any participating NHS sites in Scotland the Research Gateway will also inform NHS Research Scotland Permissions Coordinating Centre (NRSPCC) to share this with these participating sites. If you have any participating NHS sites in England/Wales then you need to send the completed review and confirmation of Pharmacy Assurance email to the participating NHS sites in England and Wales. If the review and confirmation email are available before you send out the Local Information Pack to participating NHS sites in England and Wales, you can include them as part of the Local Information Pack.
Back to the top
For self-managed studies you'll need to register the trial as self-managed with the Gateway and then work with the selected reviewer(s) to complete Pharmacy Assurance for your trial. You should therefore identify the reviewer(s) who'll complete the review before you make a submission. The sequence of events for applications made via the self-managed route is detailed below.
- You (the applicant) should send the Self-Managed Registration Form and relevant information in the covering email from the application pack to pharmacytechnicalassurance@hscni.net to begin the Pharmacy Assurance process.
- Within 7 calendar days of you submitting all the required documents to the Research Gateway, they'll:
- Ensure you plan to use HRA-registered reviewers with appropriate specialisms to review the study; and
- Email you to confirm that the study has been registered for a self-managed review. They'll also provide you with a copy of the technical pharmacy review form for the reviewer(s) to complete.
- You then request the review from the pharmacy reviewer(s) by forwarding the email from the Research Gateway and the full Pharmacy Assurance application pack.
- You and the pharmacy reviewer(s) work with one another to complete the review. There are no timelines yet set by the Research Gateway for this part of the process.
- The reviewer(s) send the completed pharmacy review to you.
- You send the completed pharmacy review to the Research Gateway (pharmacytechnicalassurance@hscni.net).
- The Research Gateway will issue confirmation of Pharmacy Assurance to
you via email and will share this with participating HSC sites in Northern Ireland. You should not that if you have any participating NHS sites in:
- Scotland then the Research Gateway will inform NHS Research Scotland Permissions Coordinating Centre (NRSPCC) to
share this with any participating sites in Scotland.
- England/Wales then you'll need to send the completed review
and confirmation of the Pharmacy Assurance email to participating NHS sites in England
and Wales. If the review and confirmation email are available before you send out the Local Information Pack to participating NHS sites in England and Wales, you can include them as part of the Local Information Pack.
Back to the top
Eligibility
Where the lead nation is Scotland, Pharmacy Assurance is available for all clinical trials involving investigational medicinal products (CTIMPs) taking place in secondary care in NHS Scotland.
Review process
Pharmacy Assurance is processed in accordance with the Scottish Coordinated Pharmacy review process. This will include assigning registered reviewers and working with you (the applicant) in case of any queries. Note: you cannot request specific reviewers when using this route. The reviewer is usually the pharmacist setting up the study at the lead site in Scotland.
There is currently no fee for using this route.
When you e-submit your IRAS application for NHS Permission it will automatically be assigned to Pharmacy Assurance / Coordinated Review via the NRS Generic Review process. You do not need to submit any separate application.
How to Apply
The sequence of events is as follows:
- When you electronically submit the IRAS application and associated documents, NHS Research Scotland Permissions Coordinating Centre (NRSPCC) will check your document set and allocate a study-wide reviewer for your project.
- The study-wide reviewer will contact their associated pharmacy reviewer to undertake the Coordinated Pharmacy Review / Pharmacy Assurance for your project. You'll receive an email if further documents are needed.
- The pharmacy reviewer sends the completed review to the study-wide reviewer.
- The study-wide reviewer will issue confirmation of Pharmacy Assurance via email.
- You send the completed review and confirmation of the Pharmacy Assurance to participating NHS/HSC sites in other nations. You should note that:
- If your study is taking place in England and/or Wales and the review and confirmation email are available before you send out the Local Information Pack to participating NHS sites in these nations, you can include them as part of the Local Information Pack.
- If you have participating HSC sites in Northern Ireland, NRSPCC will send the completed review to the Research Gateway team, who will share the review with the HSC sites.
Back to the top
The documents you'll need to include in your application include a:
protocol
Investigator's Brochure (or several if more than one is required)
Summary of Product Characteristics (SmPC)
Investigational Medicinal Product (IMP) labels as sent to the MHRA
Pharmacy Manual. You're strongly advised to provide the pharmacy manual wherever possible as it will reduce the likelihood of queries during the review. If the pharmacy manual is not provided, Pharmacy Assurance may proceed but it is advised that selected information from the pharmacy manual should be included in a covering email instead. See ‘Tips for a successful application’ for further information.
Material safety data sheet (or several if more than one is required). Pharmacy Assurance may proceed without this document, however, you're strongly advised to provide it wherever possible as it will help the reviewer(s) and reduce the likelihood of queries.a covering email (where the lead nation is England, Wales or Northern Ireland). See the below text for additional guidance relating to the content of the covering letter
The covering email where the lead nation is England, Northern Ireland or Wales should include:
- the IRAS ID
- confirmation of the lead nation
- confirmation of which UK nations are planned to participate in the trial
- the name of the lead NHS/HSC R&D office
- the full study title
- the short study title
- the following information in the table below:
Question
|
Location in the new part of IRAS for studies applying through combined review
|
Phase of CTIMP |
Medicines Information question E7 |
Total UK sample size |
Medicines Information question F4-1 |
Sponsor organisation |
Medicines Information question B1
|
Number of UK sites in the study
|
Medicines Information questions E8-3 (single site studies) or E8-4-1 (multi-site studies)
|
Confirmation of whether the study will involve primary care
|
This is not a question in the new part of IRAS. You should still confirm this within your covering email
|
Confirmation of whether any investigational medicinal products (IMPs) are advanced therapy medicinal products (ATMPs) or radiopharmaceuticals
|
Medicines Information questions D3-11-3 or D3-11-5
|
Back to the top
Errors or omissions in the application for Pharmacy Assurance may delay the progress of the review and in some instances may lead to the application being rejected. To ensure your study is processed as quickly as possible you should:
- involve an NHS/HSC trial pharmacist in the design of your study at the earliest possible stage to ensure that the trial can be conducted in the NHS/HSC (for studies with a non-commercial sponsor)
- make sure that all your documents have been submitted in accordance with instructions in the section above
- submit a pharmacy manual with the application pack. We strongly recommend this as it will reduce the number of queries during the review process. Where the pharmacy manual cannot be provided, we recommend a covering email or letter be provided to include any information from the pharmacy manual that is not included in the pharmacy technical review form. You can view an exemplar pharmacy technical review form to help with this
- ensure it's clear in your submission if your trial will have multiple parts but the UK will only be participating in certain parts of it. This will mean reviewers will only look at information for the parts that are applicable to the UK. It's recommended you highlight this in a covering email
Back to the top
It's important you note that any amendments to your trial will not be reviewed through Pharmacy Assurance. If the information contained within the technical pharmacy review form becomes outdated due to a change in the protocol or other supporting documents, please visit the guidance in the
Maintaining your Approvals section of IRAS Help.
Back to the top
We strive to ensure that the Pharmacy Assurance process is effective and efficient, and welcome all feedback on the Pharmacy Assurance process, including from sites who've received a study, which has been through Pharmacy Assurance. You can email the Technical Assurance team via
pharmacy.assurance@hra.nhs.uk to submit any feedback or comments on the service.
Back to the top
Page last updated: 23 October 2024